RxDoctor Payments Data

Shanoor Khan, PA

Physician Assistant · Corona, CANPI 1326391368

Payments from drug & device makers

$1,570in general payments, 2019–2025

Across 77 payments — averaging $20.39 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$496
  • Novo Nordisk$155
  • Pfizer$152
  • Abbott$116
  • Novartis$111
  • AbbVie$74
  • plus $465 from 13 others

What the payments were for

  • Food & beverage$1,570100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,570 in reported general payments places this provider in the 80th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$15,452
Medicare patients
121
Services billed
230

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide67$72,634
FarxigaDapagliflozin Propanediol47$46,785
EliquisApixaban21$30,995
JardianceEmpagliflozin27$25,247
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$18,977
TrulicityDulaglutide15$14,518
JanuviaSitagliptin Phosphate16$14,512
DapagliflozinDapagliflozin Propanediol21$12,923
LinzessLinaclotide21$11,996
MounjaroTirzepatide11$11,056
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$4,812
Lantus SolostarInsulin Glargine,hum.Rec.Anlog44$4,120
Rosuvastatin Calcium113$1,847
Atorvastatin Calcium173$1,601
Levothyroxine Sodium108$1,308

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$155$72,63467 claims
AstraZenecaFarxiga$496$46,78547 claims
PfizerEliquis$152$30,99521 claims
Lilly USA, LLCTrulicity, Mounjaro$68$25,57426 claims
Boehringer IngelheimJardiance$72$25,24727 claims
GSKTrelegy Ellipta$53$18,97724 claims
MerckJanuvia$56$14,51216 claims
AbbVieLinzess$74$11,99621 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Corona

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →